about
Examining the prevalence of non-criteria anti-phospholipid antibodies in patients with anti-phospholipid syndrome: a systematic reviewHLA class II alleles associations of anticardiolipin and anti-beta2GPI antibodies in a large series of European patients with systemic lupus erythematosusVariation at FCGR2A and functionally related genes is associated with the response to anti-TNF therapy in rheumatoid arthritisAntiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients.Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients.[Clinical and immunological features in 112 patients with antiphospholipid syndrome].Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients.Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review.Lack of validation of genetic variants associated with anti-tumor necrosis factor therapy response in rheumatoid arthritis: a genome-wide association study replication and meta-analysisGenome-wide pathway analysis identifies VEGF pathway association with oral ulceration in systemic lupus erythematosus.Cardiovascular disease in immune-mediated inflammatory diseases: A cross-sectional analysis of 6 cohortsRheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: a case-only studySystemic lupus erythematosus: genomics, mechanisms, and therapies.Urine metabolome profiling of immune-mediated inflammatory diseases.Comprehensive description of clinical characteristics of a large systemic lupus erythematosus cohort from the Spanish Rheumatology Society Lupus Registry (RELESSER) with emphasis on complete versus incomplete lupus differencesCardiovascular Events in Systemic Lupus Erythematosus: A Nationwide Study in Spain From the RELESSER Registry.Systemic lupus erythematosus in Europe at the change of the millennium: lessons from the "Euro-Lupus Project".Insulin resistance and levels of adipokines in patients with untreated early rheumatoid arthritisCharacterization of Patients With Lupus Nephritis Included in a Large Cohort From the Spanish Society of Rheumatology Registry of Patients With Systemic Lupus Erythematosus (RELESSER).A functional variant of TLR10 modifies the activity of NFkB and may help predict a worse prognosis in patients with rheumatoid arthritis.Analysis of the influence of PTPN22 gene polymorphisms in systemic sclerosis.2014 update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological therapies in rheumatoid arthritis.Prevalence of Comorbidities in Rheumatoid Arthritis and Evaluation of Their Monitoring in Clinical Practice: The Spanish Cohort of the COMORA Study.An MIF Promoter Polymorphism Is Associated with Susceptibility to Pulmonary Arterial Hypertension in Diffuse Cutaneous Systemic Sclerosis.Quality standards for rheumatology outpatient clinic. The EXTRELLA project.Management of cardiovascular risk in systemic lupus erythematosus: a systematic review.Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus.Eficiency of different doses of rituximab in rheumatoid arthritis.Comorbidities in Patients With Primary Sjögren's Syndrome and Systemic Lupus Erythematosus: A Comparative Registries-Based Study.Relationship between damage clustering and mortality in systemic lupus erythematosus in early and late stages of the disease: cluster analyses in a large cohort from the Spanish Society of Rheumatology Lupus Registry.FCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors.Analysis of disease activity and response to treatment in a large Spanish cohort of patients with systemic lupus erythematosus.A deletion at ADAMTS9-MAGI1 locus is associated with psoriatic arthritis risk.BANK1 functional variants are associated with susceptibility to diffuse systemic sclerosis in Caucasians.Genetic variation associated with cardiovascular risk in autoimmune diseasesMorbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients.Tocilizumab in patients with active rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs or tumor necrosis factor inhibitors: subanalysis of Spanish results of an open-label study close to clinical practice.Quality-of-care standards for early arthritis clinics.GWAS replication study confirms the association of PDE3A-SLCO1C1 with anti-TNF therapy response in rheumatoid arthritis.Incidence of cancer in a cohort of Spanish patients with systemic lupus erythematosus.
P50
Q28081765-244EB377-F861-40CB-9A9D-2D6D4A2B8E3CQ28138464-B2DA03EE-CB8E-4B3F-A0C6-10220445ACC8Q28545783-06856820-CCEB-4AE3-BC3B-417849C30B32Q33341941-017D5B8B-3D69-47BF-A8E3-EB749ECF530BQ33357081-9BDACF88-0078-45F8-A422-D2EC921140B3Q33363404-88C78ECD-238B-4765-B664-A5DD445B38F3Q33412915-D39B3EE0-7A80-410B-B701-D9C64338127AQ33415332-C2B0EE43-DF68-430C-8A64-32FAD82AABDCQ33766353-07241CC2-DBF1-47A0-8F69-BF859660D4A7Q33801959-593ACB83-8518-4C6D-B4CC-FCFB6C53B568Q33879759-A9DDBC1B-EC77-4001-ABFE-AED7E88C8E11Q35544546-D9B76EBC-5EE5-43A8-92F1-E0C68A7A8644Q36111596-0BD32EF4-6E7A-422A-8134-838DFDFA0684Q36127459-C7DDE47F-D9F1-4FF9-9E9D-B3E520EC43C9Q36152835-3D59AB1D-A208-4CE6-97E2-6211162E375DQ36153524-AC4D563C-98FD-40E8-B08B-A7C7587B246DQ36399103-A5374FF0-2AA5-4F76-B443-10F00CCDC522Q36456346-8AA4325D-A221-4285-99FB-7788BE29F786Q36663933-2FDEAA01-CA78-4CAC-A0FC-E6DEE236310BQ37310984-B9F0B383-E8CA-4E48-BEEF-63F86FC8B460Q38367681-F00F5FF0-7202-455B-9E72-F529DFD0AA2CQ38519460-9C36CB2F-5E5D-4CEA-BE17-71A9857D2CCFQ38677513-C48852E7-6107-4651-AC56-3DE6FEFC184DQ38698316-38914684-5302-4D24-933D-0411F3597439Q38699177-3A5A7285-B0C2-48C8-83FE-9540705D17AAQ39272988-A91C8F4E-2E48-4A25-86AA-06355860BA99Q40308633-80AF3AE9-0227-4769-BE1E-598E712A4926Q40441010-3275E4D0-C25C-4973-81AE-6BD89E223425Q40562190-F4C5797E-F15D-4688-BBED-47613990A429Q40831626-D1CD664D-A79D-4801-A3E4-BD208D65D2FFQ41139422-AE41D1DB-C9F4-454A-9490-92DC82809C13Q41680597-6CA24EB5-DDEC-4BE0-80AB-C005058A78C3Q41728348-ECA2F8E8-17B9-41FB-AF1B-A656C9685C53Q41886328-3CA2F503-C70F-4C31-BCDE-3D6485840387Q42370776-B8FE9586-637A-4344-8669-A877333086EDQ43519903-60F34590-0860-4EAB-961F-F2CF4D6F74CBQ44847538-5F57C608-BC4B-4A20-9A71-F2338576A529Q45910048-1C5F1FEF-E08E-4EA2-9CFF-025FFE07D731Q46626086-8252B43B-4E34-485A-B235-7F61FA729D72Q46972419-477B5530-959B-4277-ACAC-4128FCD96D6C
P50
description
Spaans onderzoeker
@nl
forsker
@nb
hulumtues
@sq
researcher
@en
հետազոտող
@hy
name
A. Fernandez-Nebro
@ast
A. Fernandez-Nebro
@nl
A. Fernandez-Nebro
@sl
Antonio Fernandez-Nebro
@en
Antonio Fernandez-Nebro
@es
Antonio Fernandez-Nebro
@nb
type
label
A. Fernandez-Nebro
@ast
A. Fernandez-Nebro
@nl
A. Fernandez-Nebro
@sl
Antonio Fernandez-Nebro
@en
Antonio Fernandez-Nebro
@es
Antonio Fernandez-Nebro
@nb
altLabel
A. Fernandez-Nebro
@en
prefLabel
A. Fernandez-Nebro
@ast
A. Fernandez-Nebro
@nl
A. Fernandez-Nebro
@sl
Antonio Fernandez-Nebro
@en
Antonio Fernandez-Nebro
@es
Antonio Fernandez-Nebro
@nb
P108
P106
P1153
6701894237
P21
P27
P31
P496
0000-0002-2962-9844